Iguratimod (IGU) is a novel synthetic small molecule disease modified anti-rheumatic drug
approved only in Japan and China up to date. IGU plays an important immunomodulatory …

Iguratimod (IGU) is a novel small-molecule anti-rheumatic drug with remarkable
effectiveness and good safety for the treatment of active rheumatoid arthritis. Its mechanism …

This study introduces a novel approach of repetitive modeling to simulate the pathological
process of recurrent gout attacks in humans. This methodology addresses the instability …

The development of biological disease-modifying antirheumatic drugs (bDMARDs) and
target synthetic DMARDs (tsDMARDs), also known as small molecule inhibitors, represent a …

Objective To explore the efficacy and safety of Iguratimod (IGU) intervention in the treatment
of Ankylosing Spondylitis (AS). Methods We used computer to search literature databases …

Autoimmune diseases are affected by complex pathophysiology involving multiple cell
types, cytokines, antibodies and mimicking factors. Different drugs are used to improve these …

Severe interstitial lung disease secondary to connective tissue diseases, characterized by
pulmonary inflammation and fibrosis, often have very poor prognosis due to lack of effective …

Background The inadequate response of some patients with rheumatoid arthritis (RA) to
current therapies is an issue that needs to be addressed. Patients with refractory RA (RRA) …

Background This study aims to evaluate the efficacy and safety of the iguratimod (IGU) as
monotherapy or combined therapy in patients with rheumatoid arthritis (RA) by using meta …

Objective Our study aimed to investigate the effect of Iguratimod (IGU) on bleomycin (BLM)-
induced interstitial lung disease (ILD). Methods The pulmonary fibrosis model group mice …